KLK3 and posterior cortical atrophy: Patients with PCa diagnosed via biopsy, with at least one high-risk feature according to the NCCN guidelines (initial PSA ≥20 ng/mL, GS ≥8, or clinical T stage ≥3a), and having undergone either RP or EBRT.